Strata Critical Medical (SRTA)
Market Price (6/28/2026): $5.295 | Market Cap: $451.8 MilSector: Health Care | Industry: Health Care Facilities
Strata Critical Medical (SRTA)
Market Price (6/28/2026): $5.295Market Cap: $451.8 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 10%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 6.1% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -12% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 44% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Remote Patient Monitoring, Health Data Analytics, and AI in Healthcare Management. | Weak multi-year price returns2Y Excs Rtn is -13%, 3Y Excs Rtn is -47% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.8% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -23% |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 10%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 6.1% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -12% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 44% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Remote Patient Monitoring, Health Data Analytics, and AI in Healthcare Management. |
| Weak multi-year price returns2Y Excs Rtn is -13%, 3Y Excs Rtn is -47% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.8% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -23% |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/26/2026
Strata Critical Medical (SRTA) stock has gained about 25% since 2/28/2026 because of the following key factors:
1. Strata Critical Medical (SRTA) delivered strong financial results for fiscal Q1 2026 (ended March 31, 2026), reporting earnings per share (EPS) of $0.03, which significantly beat analyst estimates of a -$0.0383 loss by 178.33%. Additionally, revenue for the quarter increased by 87.4% year-over-year to $67.4 million, surpassing analyst expectations by approximately $2.4 million. This turnaround to profitability, alongside substantial revenue growth, indicated improving operational performance.
2. The company aggressively pursued strategic acquisitions, expanding its critical medical services portfolio. A notable acquisition was Louisville Perfusion Services, Inc., completed on June 2, 2026, for an upfront consideration of approximately $16 million out of a total $20 million. This acquisition, coupled with the prior Keystone Perfusion Services (August 2025) and Ohio Valley Perfusion Associates (fiscal Q1 2026) deals, diversified SRTA's offerings and was cited as a reason for an 8.5% stock surge on June 16, 2026.
Show more
Strata Critical Medical (SRTA) stock has gained about 25% since 2/28/2026 because of the following key factors:
1. Strata Critical Medical (SRTA) delivered strong financial results for fiscal Q1 2026 (ended March 31, 2026), reporting earnings per share (EPS) of $0.03, which significantly beat analyst estimates of a -$0.0383 loss by 178.33%. Additionally, revenue for the quarter increased by 87.4% year-over-year to $67.4 million, surpassing analyst expectations by approximately $2.4 million. This turnaround to profitability, alongside substantial revenue growth, indicated improving operational performance.
2. The company aggressively pursued strategic acquisitions, expanding its critical medical services portfolio. A notable acquisition was Louisville Perfusion Services, Inc., completed on June 2, 2026, for an upfront consideration of approximately $16 million out of a total $20 million. This acquisition, coupled with the prior Keystone Perfusion Services (August 2025) and Ohio Valley Perfusion Associates (fiscal Q1 2026) deals, diversified SRTA's offerings and was cited as a reason for an 8.5% stock surge on June 16, 2026.
Show more
Updated on 6/26/2026
Strata Critical Medical (SRTA) stock has gained about 25% since 2/28/2026 because of the following key factors:
1. Strata Critical Medical (SRTA) delivered strong financial results for fiscal Q1 2026 (ended March 31, 2026), reporting earnings per share (EPS) of $0.03, which significantly beat analyst estimates of a -$0.0383 loss by 178.33%. Additionally, revenue for the quarter increased by 87.4% year-over-year to $67.4 million, surpassing analyst expectations by approximately $2.4 million. This turnaround to profitability, alongside substantial revenue growth, indicated improving operational performance.
2. The company aggressively pursued strategic acquisitions, expanding its critical medical services portfolio. A notable acquisition was Louisville Perfusion Services, Inc., completed on June 2, 2026, for an upfront consideration of approximately $16 million out of a total $20 million. This acquisition, coupled with the prior Keystone Perfusion Services (August 2025) and Ohio Valley Perfusion Associates (fiscal Q1 2026) deals, diversified SRTA's offerings and was cited as a reason for an 8.5% stock surge on June 16, 2026.
3. Analyst sentiment remained highly positive, with several firms raising their price targets for SRTA. As of June 26, 2026, Wall Street analysts projected a significant upside of approximately 70% to a consensus price target of $7.25, with some individual targets reaching $11.50. This bullish outlook was primarily driven by the company's strategic acquisitions, its unique and defensible market position in organ transplant logistics and medical services, and a clearer anticipated path to sustained profitability.
Show less
Strata Critical Medical (SRTA) stock has gained about 25% since 2/28/2026 because of the following key factors:
1. Strata Critical Medical (SRTA) delivered strong financial results for fiscal Q1 2026 (ended March 31, 2026), reporting earnings per share (EPS) of $0.03, which significantly beat analyst estimates of a -$0.0383 loss by 178.33%. Additionally, revenue for the quarter increased by 87.4% year-over-year to $67.4 million, surpassing analyst expectations by approximately $2.4 million. This turnaround to profitability, alongside substantial revenue growth, indicated improving operational performance.
2. The company aggressively pursued strategic acquisitions, expanding its critical medical services portfolio. A notable acquisition was Louisville Perfusion Services, Inc., completed on June 2, 2026, for an upfront consideration of approximately $16 million out of a total $20 million. This acquisition, coupled with the prior Keystone Perfusion Services (August 2025) and Ohio Valley Perfusion Associates (fiscal Q1 2026) deals, diversified SRTA's offerings and was cited as a reason for an 8.5% stock surge on June 16, 2026.
3. Analyst sentiment remained highly positive, with several firms raising their price targets for SRTA. As of June 26, 2026, Wall Street analysts projected a significant upside of approximately 70% to a consensus price target of $7.25, with some individual targets reaching $11.50. This bullish outlook was primarily driven by the company's strategic acquisitions, its unique and defensible market position in organ transplant logistics and medical services, and a clearer anticipated path to sustained profitability.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 23.8% change in SRTA stock from 2/28/2026 to 6/27/2026 was primarily driven by a 32.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.28 | 5.30 | 23.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 192 | 254 | 32.1% |
| Net Income Margin (%) | 21.0% | 18.5% | -11.9% |
| P/E Multiple | 8.7 | 9.6 | 10.1% |
| Shares Outstanding (Mil) | 82 | 85 | -3.4% |
| Cumulative Contribution | 23.8% |
Market Drivers
2/28/2026 to 6/27/2026| Return | Correlation | |
|---|---|---|
| SRTA | 23.8% | |
| Market (SPY) | 6.6% | 59.8% |
| Sector (XLV) | 0.5% | 7.3% |
Fundamental Drivers
The 22.1% change in SRTA stock from 11/30/2025 to 6/27/2026 was primarily driven by a 32.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.34 | 5.30 | 22.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 192 | 254 | 32.1% |
| Net Income Margin (%) | 21.0% | 18.5% | -11.9% |
| P/E Multiple | 8.9 | 9.6 | 8.6% |
| Shares Outstanding (Mil) | 82 | 85 | -3.4% |
| Cumulative Contribution | 22.1% |
Market Drivers
11/30/2025 to 6/27/2026| Return | Correlation | |
|---|---|---|
| SRTA | 22.1% | |
| Market (SPY) | 7.3% | 46.5% |
| Sector (XLV) | 2.6% | 6.9% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2025 to 6/27/2026| Return | Correlation | |
|---|---|---|
| SRTA | ||
| Market (SPY) | 25.1% | 45.4% |
| Sector (XLV) | 23.0% | 12.8% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2023 to 6/27/2026| Return | Correlation | |
|---|---|---|
| SRTA | ||
| Market (SPY) | 81.3% | 45.4% |
| Sector (XLV) | 31.9% | 12.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SRTA Return | - | - | - | - | 10% | 11% | 23% |
| Peers Return | 59% | 24% | -2% | -8% | 14% | 26% | 158% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| SRTA Win Rate | - | - | - | - | 40% | 50% | |
| Peers Win Rate | 52% | 48% | 42% | 44% | 44% | 67% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| SRTA Max Drawdown | - | - | - | - | - | -32% | |
| Peers Max Drawdown | -41% | -57% | -58% | -55% | -40% | -34% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMDX, CYRX, CCRN, BLFS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/26/2026 (YTD)
How Low Can It Go
SRTA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
SRTA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Strata Critical Medical (SRTA)
Blade Air Mobility, Inc., trading under the symbol SRTA, provides premium air transportation services designed to offer efficient alternatives to congested ground routes within the United States. The company's core business revolves around minimizing travel time and improving convenience for passengers by leveraging airborne solutions.
The company's main products and services include both charter flights and by-the-seat bookings. These services utilize a diverse fleet of aircraft, including helicopters, jets, turboprops, and amphibious seaplanes, allowing for flexible travel solutions tailored to various distances and passenger needs.
Blade Air Mobility primarily serves customers within the United States who are looking for rapid and direct travel options, particularly in areas where ground transportation is time-consuming. Its market consists of individuals and businesses seeking faster, more convenient, and often point-to-point travel experiences compared to traditional commuting methods.
AI Analysis | Feedback
- Uber/Lyft for urban and regional air transportation via helicopters and seaplanes.
- Like NetJets, but for by-the-seat bookings on helicopters and small aircraft for quick, short-distance routes.
AI Analysis | Feedback
- Charter Flights: Private air transportation services for individuals or groups using helicopters, jets, turboprops, and amphibious seaplanes.
- By-the-Seat Flights: Scheduled air transportation services where passengers can book individual seats on helicopters, jets, turboprops, and amphibious seaplanes.
AI Analysis | Feedback
null
AI Analysis | Feedback
- Helijet Charters Inc.
AI Analysis | Feedback
Melissa M. Tomkiel, Co-Chief Executive Officer and General Counsel
- Melissa Tomkiel is the Co-CEO and General Counsel of Strata Critical Medical, Inc.. She also serves on Strata's board of directors.
- Before her current role, she served as President and General Counsel of Blade Air Mobility, the predecessor company to Strata, which she joined in 2015.
- Prior to Blade, Ms. Tomkiel co-founded and was President of Fly The Whale, a commuter air carrier operating amphibious seaplanes and rotorcraft. She began her career as an attorney at Pryor Cashman.
- Ms. Tomkiel was appointed Co-CEO when Blade Air Mobility rebranded to Strata Critical Medical in August 2025. She has made significant stock purchases in Strata (SRTA).
William A. Heyburn, Co-Chief Executive Officer and Chief Financial Officer
- William Heyburn is the Co-CEO and Chief Financial Officer of Strata Critical Medical, Inc., and also serves as a director.
- He previously held the positions of Chief Financial Officer and Head of Corporate Development at Blade Air Mobility, which he joined in 2018.
- Before joining Blade Air Mobility, Mr. Heyburn was a Vice President at RedBird Capital Partners, a principal investment firm specializing in growth equity, build-up, and structured equity investments.
- He was appointed Co-CEO and CFO in August 2025, concurrent with the company's rebranding. He purchased 17,000 shares of Strata Critical Medical Inc on December 9, 2025.
Scott M. Wunsch, Chief Executive Officer, Logistics
- Scott Wunsch is the CEO of Strata's Logistics business.
- He joined Trinity Medical Solutions in 2018, a company later acquired by Strata in 2021.
- Prior to Trinity, Mr. Wunsch spent 13 years at LifeCenter Northwest, where he was the Vice President of Clinical Operations, managing overall operations and logistics for one of the largest geographic organ procurement organizations in the country.
Amir M. Cohen, Chief Accounting & Integration Officer
- Amir Cohen is Strata's Chief Accounting & Integration Officer.
- He played a key role in building the company's accounting organization through its transition from private to public and led significant aspects of the passenger-business carve-out.
- Before joining Strata, Mr. Cohen held senior finance roles at various WPP agencies and WPP's global headquarters, and previously worked as a manager at PwC. He holds an MBA from NYU Stern and is a CPA.
Mathew Schneider, Vice President of Finance and Investor Relations, and CFO of Clinical Services
- Mathew Schneider has served as Strata's Vice President of Finance and Investor Relations since April 2024 and as Chief Financial Officer of Strata's Clinical Services business since October 2025.
- Prior to Strata, he worked as a senior analyst at Holocene Advisors L.P. and an analyst at Glenhill Capital L.P., focusing on the Industrial sector.
- Mr. Schneider also served as a Vice President in Morgan Stanley's equity research division and an Associate in UBS's equity research division.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Strata Critical Medical (symbol: SRTA) focuses on time-critical logistics and specialized medical services for the U.S. healthcare industry. The company, which was formerly known as Blade Air Mobility, Inc., rebranded to Strata Critical Medical, Inc. in August 2025 after selling its passenger division.
Strata Critical Medical's main products and services include air and ground transportation for human organs, transplant teams, and related medical materials, as well as organ placement services. It also provides transplant clinical services such as organ recovery procedures, normothermic regional perfusion, and preservation services. Additionally, the company offers cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals.
The company plays a significant role in the U.S. organ transport market, dominating approximately 90% of this sector.
The addressable markets for Strata Critical Medical's main products and services are primarily within the United States:
- Organ Transport Service Market (U.S.): The global organ transport service market is projected to grow from USD 4.40 billion in 2025 to USD 4.74 billion in 2026, and further to USD 9.40 billion by 2035. North America accounts for approximately 41% of this global market. The U.S. organ transport service market is anticipated to experience substantial growth due to increasing organ transplant procedures and advancements in medical technologies.
- U.S. Transplantation Market: The U.S. transplantation market size was valued at USD 3.40 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 9.1% during the forecast period.
- Organ Preservation Market (U.S.): The global organ preservation market size was USD 280.7 million in 2024 and is expected to reach USD 510.0 million by 2032, growing at a CAGR of 7.9% during 2025–2032. The U.S. performed 48,149 transplants in 2024, indicating a high demand for organ preservation solutions.
Strata Critical Medical's projected revenues were between $160 million and $170 million for 2025, and the company has raised its 2026 revenue guidance to between $260 million and $275 million.
AI Analysis | Feedback
null
AI Analysis | Feedback
The company Strata Critical Medical, Inc. (SRTA) provides time-critical logistics and medical services to the healthcare industry in the United States. It was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025, at which point its ticker changed from BLDE to SRTA. The company focuses on services such as air and ground transportation for human organs, transplant teams, and related medical materials.
Here is a summary of Strata Critical Medical's capital allocation decisions over the last 3-5 years, reflecting its operations as Blade Air Mobility's medical division and subsequently as Strata Critical Medical:
Capital Allocation Decisions
- Share Issuance
- Strata Critical Medical had 86.4 million shares outstanding as of February 23, 2026.
- As of March 14, 2026, the company had 86.99 million shares outstanding.
- Inbound Investments
- Strata announced the closing of a revolving credit facility in February 2026 to support its acquisition strategy execution.
- Outbound Investments
- Strata Critical Medical aims to strategically expand its portfolio of services through acquisition and organic growth.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 16.00 |
| Mkt Cap | 0.8 |
| Rev LTM | 254 |
| Op Inc LTM | -15 |
| FCF LTM | -2 |
| FCF 3Y Avg | -37 |
| CFO LTM | 18 |
| CFO 3Y Avg | 6 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 27.5% |
| Rev Chg 3Y Avg | 12.6% |
| Rev Chg Q | 21.2% |
| QoQ Delta Rev Chg LTM | 5.0% |
| Op Inc Chg LTM | 17.5% |
| Op Inc Chg 3Y Avg | -11.7% |
| Op Mgn LTM | -7.8% |
| Op Mgn 3Y Avg | -14.5% |
| QoQ Delta Op Mgn LTM | -0.3% |
| CFO/Rev LTM | 4.7% |
| CFO/Rev 3Y Avg | 3.9% |
| FCF/Rev LTM | -1.8% |
| FCF/Rev 3Y Avg | -16.7% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Logistics | 177 | 147 | |||
| Clinical | 20 | 0 | |||
| Medical | 127 | 72 | |||
| Passenger | 99 | 74 | |||
| MediMobility Organ Transport and Jet | 26 | ||||
| Other | 2 | ||||
| Short Distance | 22 | ||||
| Total | 197 | 147 | 225 | 146 | 51 |
| $ Mil | 2024 | 2023 | 2022 |
|---|---|---|---|
| Medical | 19 | 11 | -3 |
| Passenger | 4 | -5 | -14 |
| Gain on lease modification | 1 | ||
| Executive severance costs | -0 | -0 | |
| M&A transaction costs | -0 | ||
| SOX readiness costs | -0 | -0 | |
| Restructuring costs | -1 | ||
| Legal and regulatory advocacy fees | -2 | -1 | |
| Impairment of intangible assets | -6 | -21 | |
| Depreciation and amortization | -6 | -7 | |
| Stock-based compensation | -20 | -13 | |
| Adjusted unallocated corporate expenses and software development | -22 | -22 | -37 |
| Contingent consideration compensation (earn-out) | -10 | ||
| Total | -34 | -68 | -54 |
Price Behavior
Price Behavior
| Market Price | $5.30 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 09/13/2019 | |
| Distance from 52W High | -18.1% | |
| 50 Days | 200 Days | |
| DMA Price | $4.84 | $4.83 |
| DMA Trend | up | up |
| Distance from DMA | 9.6% | 9.6% |
| 3M | 1YR | |
| Volatility | 53.8% | 61.5% |
| Downside Capture | 260.42 | 201.59 |
| Upside Capture | 221.29 | 192.65 |
| Correlation (SPY) | 60.2% |
SRTA Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.34 | 2.39 | 1.97 | 1.98 | -0.19 | -0.23 |
| Up Beta | 5.33 | 2.32 | 1.37 | 1.54 | 0.19 | 0.21 |
| Down Beta | 4.99 | 1.58 | 2.07 | 1.93 | -0.29 | -0.03 |
| Up Capture | 465% | 315% | 320% | 322% | 196% | 18% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 13 | 26 | 37 | 62 | 91 | 91 |
| Down Capture | 332% | 232% | 167% | 169% | 136% | 68% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 7 | 14 | 25 | 61 | 94 | 94 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SRTA | |
|---|---|---|---|---|
| SRTA | 21.4% | 61.5% | 0.62 | - |
| Sector ETF (XLV) | 21.4% | 15.4% | 1.06 | 12.8% |
| Equity (SPY) | 21.2% | 12.4% | 1.26 | 45.4% |
| Gold (GLD) | 21.8% | 27.7% | 0.70 | 25.4% |
| Commodities (DBC) | 21.8% | 18.6% | 0.92 | -3.1% |
| Real Estate (VNQ) | 16.1% | 13.6% | 0.85 | 19.8% |
| Bitcoin (BTCUSD) | -44.2% | 42.5% | -1.25 | 35.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SRTA | |
|---|---|---|---|---|
| SRTA | 3.9% | 61.5% | 0.62 | - |
| Sector ETF (XLV) | 7.0% | 14.8% | 0.29 | 12.8% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 45.4% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 25.4% |
| Commodities (DBC) | 7.4% | 19.5% | 0.28 | -3.1% |
| Real Estate (VNQ) | 3.4% | 18.9% | 0.08 | 19.8% |
| Bitcoin (BTCUSD) | 10.9% | 54.0% | 0.39 | 35.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SRTA | |
|---|---|---|---|---|
| SRTA | 1.9% | 61.5% | 0.62 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.51 | 12.8% |
| Equity (SPY) | 15.2% | 18.0% | 0.72 | 45.4% |
| Gold (GLD) | 11.8% | 16.1% | 0.60 | 25.4% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | -3.1% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 19.8% |
| Bitcoin (BTCUSD) | 54.7% | 66.4% | 0.95 | 35.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 10.6% | 13.5% | 29.9% |
| 3/3/2026 | 6.9% | 1.8% | -6.9% |
| 11/10/2025 | 9.5% | 8.1% | 4.3% |
| SUMMARY STATS | |||
| # Positive | 3 | 3 | 2 |
| # Negative | 0 | 0 | 1 |
| Median Positive | 9.5% | 8.1% | 17.1% |
| Median Negative | -6.9% | ||
| Max Positive | 10.6% | 13.5% | 29.9% |
| Max Negative | -6.9% | ||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 10.6% | 13.5% | 29.9% |
| 3/3/2026 | 6.9% | 1.8% | -6.9% |
| 11/10/2025 | 9.5% | 8.1% | 4.3% |
| SUMMARY STATS | |||
| # Positive | 3 | 3 | 2 |
| # Negative | 0 | 0 | 1 |
| Median Positive | 9.5% | 8.1% | 17.1% |
| Median Negative | -6.9% | ||
| Max Positive | 10.6% | 13.5% | 29.9% |
| Max Negative | -6.9% | ||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 02/10/2022 | 10-QT |
| 09/30/2021 | 12/20/2021 | 10-K |
| 06/30/2021 | 08/16/2021 | 10-Q |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 260.00 Mil | 267.50 Mil | 275.00 Mil | 0 | Affirmed | Guidance: 267.50 Mil for 2026 | |
| 2026 Adjusted EBITDA | 29.00 Mil | 31.00 Mil | 33.00 Mil | 3.3% | Raised | Guidance: 30.00 Mil for 2026 | |
| 2026 Free Cash Flow | 15.00 Mil | 18.50 Mil | 22.00 Mil | 0 | Affirmed | Guidance: 18.50 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 3/3/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 260.00 Mil | 267.50 Mil | 275.00 Mil | 40.8% | Raised | Guidance: 190.00 Mil for 2025 | |
| 2026 Adjusted EBITDA | 29.00 Mil | 31.00 Mil | 33.00 Mil | 129.6% | Raised | Guidance: 13.50 Mil for 2025 | |
| 2026 Free Cash Flow | 15.00 Mil | 18.50 Mil | 22.00 Mil | Higher New | |||
| 2026 Adjusted EBITDA Growth Rate | 30.0% | Higher New | |||||
Insider Activity
Updated 6/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Heyburn, William A | Co-CEO and CFO | Direct | Sell | 6102026 | 5.87 | 31,671 | 185,909 | 9,092,612 | Form |
| 2 | Cohen, Amir | Chief Accounting Officer | Direct | Sell | 6102026 | 5.87 | 4,655 | 27,325 | 860,589 | Form |
| 3 | Tomkiel, Melissa M | Co-CEO and General Counsel | Direct | Sell | 6102026 | 5.87 | 29,730 | 174,515 | 11,110,583 | Form |
| 4 | Wunsch, Scott M | CEO, Logistics | Direct | Sell | 6102026 | 5.87 | 5,550 | 32,578 | 3,672,119 | Form |
| 5 | Cohen, Amir | Chief Accounting Officer | Direct | Sell | 5262026 | 5.91 | 40,575 | 239,798 | 893,964 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Heyburn, William A | Co-CEO and CFO | Direct | Sell | 6102026 | 5.87 | 31,671 | 185,909 | 9,092,612 | Form |
| 2 | Cohen, Amir | Chief Accounting Officer | Direct | Sell | 6102026 | 5.87 | 4,655 | 27,325 | 860,589 | Form |
| 3 | Tomkiel, Melissa M | Co-CEO and General Counsel | Direct | Sell | 6102026 | 5.87 | 29,730 | 174,515 | 11,110,583 | Form |
| 4 | Wunsch, Scott M | CEO, Logistics | Direct | Sell | 6102026 | 5.87 | 5,550 | 32,578 | 3,672,119 | Form |
| 5 | Cohen, Amir | Chief Accounting Officer | Direct | Sell | 5262026 | 5.91 | 40,575 | 239,798 | 893,964 | Form |
| 6 | Cohen, Amir | Chief Accounting Officer | Direct | Sell | 5262026 | 5.79 | 10,300 | 59,637 | 1,110,742 | Form |
| 7 | Cohen, Amir | Chief Accounting Officer | Direct | Sell | 5132026 | 5.79 | 14,306 | 82,832 | 1,170,379 | Form |
| 8 | Heyburn, William A | Co-CEO and CFO | Direct | Buy | 12102025 | 4.47 | 17,000 | 76,044 | 6,277,850 | Form |
| 9 | Lauck, Andrew | Direct | Buy | 12052025 | 4.37 | 5,000 | 21,825 | 592,077 | Form | |
| 10 | Love, Reginald | Direct | Sell | 11242025 | 4.37 | 11,000 | 48,070 | 497,730 | Form | |
| 11 | Love, Reginald | Direct | Sell | 11202025 | 4.31 | 11,000 | 47,434 | 538,581 | Form | |
| 12 | Tomkiel, Melissa M | President and General Counsel | Direct | Sell | 8052025 | 4.94 | 47,995 | 237,134 | 5,676,159 | Form |
| 13 | Heyburn, William A | Chief Financial Officer | Direct | Sell | 8052025 | 4.94 | 46,918 | 231,822 | 6,625,115 | Form |
| 14 | Tomkiel, Melissa M | President and General Counsel | Direct | Sell | 6112025 | 4.08 | 100,000 | 407,530 | 4,691,502 | Form |
| 15 | Heyburn, William A | Chief Financial Officer | Direct | Sell | 6112025 | 4.07 | 100,000 | 406,590 | 5,529,632 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/27/2026